Nov 4, 2026 | News, Risk Management
Following the FDA’s authorization of Lynch Regenerative Medicine’s (LRM) Investigational New Drug (IND) application (announced October 21, 2026), the clinical study evaluating injectable recombinant human platelet-derived growth factor-BB (rhPDGF-BB) has officially...
Oct 21, 2026 | News, Risk Management
On October 21, 2026, Franklin, Tennessee-based Lynch Regenerative Medicine, LLC (LRM) announced that the U.S. Food and Drug Administration (FDA) has authorized its Investigational New Drug (IND) application to proceed with a Phase 2 clinical trial evaluating...
Sep 29, 2026 | Legal Compliance, Risk Management
As of September 2026, a growing number of personal-injury lawsuits target the pharmaceutical manufacturers behind popular GLP-1 receptor agonists, including Ozempic, Wegovy, Trulicity, Mounjaro, and Zepbound. The core legal allegation is that manufacturers failed to...
Sep 2, 2026 | Legal Compliance, News, Risk Management
The U.S. Food and Drug Administration (FDA) has issued a detailed Warning Letter (CBER 26-726330) to Scottsdale, Arizona-based R3 Medical Companies, its affiliated entities Bello Bio, LLC and Regen Suppliers, LLC, and CEO David L. Greene, M.D. Following joint facility...
Aug 21, 2026 | News, Risk Management
Revance Therapeutics and Teoxane have officially announced FDA approval for RHA Redensity® Eye, expanding the Teoxane RHA® Collection into the delicate infraorbital region. The hyaluronic acid (HA) filler is specifically indicated for correcting moderate to severe...
Dec 12, 2025 | Legal Compliance, Risk Management
Introduction As more Nurse Practitioners (NPs) earn doctoral-level degrees, many understandably want to acknowledge their hard-earned credentials by using the title “Dr.” in clinical and professional settings. However, state laws, medical-board rules, and recent...